Five years later, we can tell the tale of using the tools of science, we were able to turn the tide on SARS-CoV-2 and ... which rely on lipid nanoparticles (LNPs) for mRNA protection and cellular ...

At a time when global coordination against health threats is critical, recent policy shifts in the U.S. have created a ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

DNA delivery using lipid ... the lipid nanoparticles mitigates this toxicity and enables prolonged gene expression. The likelihood of severe COVID-19 increases with age upon SARS-CoV-2 infection ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepointNo anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood ...

Bioengineering Professor Michael Mitchell is using lipid nanoparticles to facilitate the delivery ... the immune system to recognize different spike proteins in the evolving SARS-CoV-2 virus.” ...

The current vaccines in the market use lipid delivery technology to deliver mRNA to induce ... which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...